Akari Therapeutics (AKTX) Competitors $0.79 +0.02 (+2.47%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$0.79 +0.01 (+0.63%) As of 09/12/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. ELUT, XBIT, ANIX, VIRI, CELU, OVID, CRDL, ORMP, VXRT, and CRVOShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Elutia (ELUT), XBiotech (XBIT), Anixa Biosciences (ANIX), Virios Therapeutics (VIRI), Celularity (CELU), Ovid Therapeutics (OVID), Cardiol Therapeutics (CRDL), Oramed Pharmaceuticals (ORMP), Vaxart (VXRT), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Its Competitors Elutia XBiotech Anixa Biosciences Virios Therapeutics Celularity Ovid Therapeutics Cardiol Therapeutics Oramed Pharmaceuticals Vaxart CervoMed Elutia (NASDAQ:ELUT) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk. Does the media favor ELUT or AKTX? In the previous week, Elutia had 6 more articles in the media than Akari Therapeutics. MarketBeat recorded 11 mentions for Elutia and 5 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.82 beat Elutia's score of 0.34 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elutia 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Akari Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in ELUT or AKTX? 74.0% of Elutia shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 27.6% of Elutia shares are held by company insiders. Comparatively, 38.1% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, ELUT or AKTX? Elutia has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Do analysts prefer ELUT or AKTX? Elutia presently has a consensus target price of $7.00, suggesting a potential upside of 446.88%. Akari Therapeutics has a consensus target price of $3.30, suggesting a potential upside of 318.25%. Given Elutia's higher possible upside, equities research analysts plainly believe Elutia is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, ELUT or AKTX? Akari Therapeutics has lower revenue, but higher earnings than Elutia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElutia$24.38M2.23-$53.95M-$1.06-1.21Akari TherapeuticsN/AN/A-$19.79MN/AN/A Is ELUT or AKTX more profitable? Akari Therapeutics has a net margin of 0.00% compared to Elutia's net margin of -90.01%. Elutia's return on equity of 0.00% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Elutia-90.01% N/A -54.08% Akari Therapeutics N/A -78.03%-31.62% SummaryElutia beats Akari Therapeutics on 6 of the 11 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.74M$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E RatioN/A21.5775.4226.02Price / SalesN/A254.90465.2991.11Price / CashN/A44.4425.8129.91Price / Book0.949.6112.626.25Net Income-$19.79M-$53.29M$3.29B$270.76M7 Day Performance-7.18%0.57%0.86%2.54%1 Month Performance-21.87%4.56%4.69%5.73%1 Year Performance-75.76%10.44%68.00%25.85% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari Therapeutics3.7234 of 5 stars$0.79+2.5%$3.30+318.3%-75.8%$25.74MN/A0.009Short Interest ↓ELUTElutia3.0959 of 5 stars$2.28-2.1%$8.00+250.9%-70.2%$96.66M$24.38M-2.15180XBITXBiotech2.1312 of 5 stars$3.16-6.8%N/A-61.0%$96.34M$4.01M-3.43100News CoverageShort Interest ↓ANIXAnixa Biosciences3.115 of 5 stars$2.99-0.7%$9.00+201.0%-12.5%$96.31M$210K-7.875Earnings ReportAnalyst RevisionVIRIVirios TherapeuticsN/A$4.96+3.4%$5.00+0.8%+2,409.0%$95.52MN/A-18.375CELUCelularity1.6921 of 5 stars$3.94+2.3%$6.00+52.3%-17.1%$94.36M$54.22M-1.24220OVIDOvid Therapeutics4.4683 of 5 stars$1.28+2.4%$3.10+142.2%+5.9%$91.02M$570K-2.4260CRDLCardiol Therapeutics2.3167 of 5 stars$1.08-0.9%$8.00+640.7%-56.9%$90.41MN/A-3.1820Positive NewsShort Interest ↑ORMPOramed Pharmaceuticals0.7363 of 5 stars$2.20flatN/A-3.2%$90.21M$1.34M-6.2910Positive NewsVXRTVaxart2.0278 of 5 stars$0.39+8.3%$2.00+412.8%-60.5%$89.28M$47.40M-1.44120Gap DownCRVOCervoMed3.8301 of 5 stars$9.62+3.2%$23.71+146.5%-49.5%$89.01M$9.74M-3.694 Related Companies and Tools Related Companies Elutia Competitors XBiotech Competitors Anixa Biosciences Competitors Virios Therapeutics Competitors Celularity Competitors Ovid Therapeutics Competitors Cardiol Therapeutics Competitors Oramed Pharmaceuticals Competitors Vaxart Competitors CervoMed Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKTX Stock Alerts